Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Emerging evidence has indicated that abnormal microRNAs (miRNAs) participated in carcinogenesis and tumor progression in
hepatocellular carcinoma
(
HCC
). Better understanding the association between miRNAs and
HCC
may contribute to discover novel therapeutic approaches for diagnosis and treatments. In the current study, we have shown that miR-1204 level was elevated in
HCC
tissues and cell lines, which was associated with malignant clinical features, including large tumor size and advanced TNM stage. Furthermore, gain-or loss-of function assays demonstrated that miR-1204 promoted cell proliferation
in vitro
and tumor growth
in vivo
as well as inhibited apoptosis
in vitro
. Luciferase reporter gene assays confirmed that
ZNF418
was a direct downstream target of miR-1204. Recuse assays showed that
ZNF418
mediates the biological function of miR-1204 on
HCC
cells through regulating MAPK and c-Jun signaling. In conclusion, our results suggest that miR-1204 functions as an oncogene to promote proliferation and inhibit apoptosis through regulating MAPK and c-Jun signaling by targeting
ZNF418
, and potentially serves as a novel prognostic biomarker and therapeutic target for
HCC
.
...
PMID:miR-1204 promotes hepatocellular carcinoma progression through activating MAPK and c-Jun/AP1 signaling by targeting ZNF418. 3133 80